Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276)

Market Cap	319.14B
Revenue (ttm)	26.00B
Net Income (ttm)	5.45B
Shares Out	6.36B
EPS (ttm)	0.86
PE Ratio	58.37
Forward PE	53.96
Dividend	0.20 (0.40%)
Ex-Dividend Date	Jul 12, 2024

Volume	26,030,458
Open	47.24
Previous Close	47.20
Day's Range	46.84 - 47.80
52-Week Range	35.51 - 57.53
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 19,611
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2023, Jiangsu Hengrui Medicine's revenue was 22.82 billion, an increase of 7.26% compared to the previous year's 21.28 billion. Earnings were 4.30 billion, an increase of 10.14%.